| 发明名称 |
FREE NGAL AS A BIOMARKER FOR CANCER |
| 摘要 |
Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer. |
| 申请公布号 |
US2014242616(A1) |
申请公布日期 |
2014.08.28 |
| 申请号 |
US201314030868 |
申请日期 |
2013.09.18 |
| 申请人 |
Children's Medical Center Corporation |
发明人 |
Moses Marsha A.;Yang Jiang |
| 分类号 |
G01N33/574 |
主分类号 |
G01N33/574 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for determining if an individual is at risk of developing, or has developed, cancer, comprising the steps of:
a) determining a level of free NGAL in a test urine sample obtained from an individual; b) comparing the level of free NGAL in the test urine sample with a control level of free NGAL; wherein a level of free NGAL in the test sample higher than a control level of free NGAL indicates that the individual is either at increased risk for developing cancer, or has cancer. |
| 地址 |
Boston MA US |
